China Medical Association Tuberculosis Society Honors Lilly with Best Partner Award
Guest blog from Lilly's Vice President of Global Health Programs and Access, Dr. Evan Lee.
The Eli Lilly and Company Foundation was honored to receive the Best Partner Award at the China Medical Association Tuberculosis (CMA TB) Society 2013 Annual Academic Congress, which took place in Chongqing, China on July 18-20. This is very special recognition, as it is the first time the CMA TB Society has granted these awards to companies and institutional partners for their efforts against TB.
Lilly has been deeply committed to the global fight against MDR-TB for more than a decade. Since its launch in 2003 we have made significant investments of over $150 million in combined value through funding, donated product, and volunteer expertise via the Lilly MDR-TB Partnership. We are continuing our commitment through 2016, with an additional funding of $30 million and continued sharing of our expertise, to focus on strengthening the capacity of healthcare professionals to detect and manage MDR-TB, and to improve access to safe, effective and quality-assured second-line TB drugs.
